Zillow Group, Inc. Class C (Z)

Zillow Group, Inc. (ZG) Presents at Barclays 23rd Annual Global Technology Conference Transcript

Designation expands (Z)-Endoxifen program into rare pediatric neuromuscular disease and may qualify Atossa for a future Priority Review Voucher upon approval SEATTLE , Dec. 11, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today announced that the U.S. Food and Drug Administration ("FDA") has granted Rare Pediatric Disease ("RPD") designation to (Z)-Endoxifen for the treatment of Duchenne Muscular Dystrophy ("DMD"). RPD designation is granted to drug candidates intended to treat serious or life-threatening diseases that primarily affect individuals from birth to 18 years of age.

Zillow offers the most compelling, lower-risk way to play a housing market rebound, leveraging dominant market share and asset-light operations. Zillow's diversified revenue streams, especially rentals (25% of revenue, growing 36%), provide resilience and operating leverage even in a sluggish housing cycle. With housing near a cyclical trough and interest rates poised to decline, Zillow is positioned for strong multi-year returns as the market recovers.

New patent further strengthens global intellectual property estate supporting Atossa's lead program across the breast cancer spectrum and other hormone-driven conditions SEATTLE , Dec. 9, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative therapies in areas of significant unmet need in breast cancer, today announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 12,479,790 B2, titled, "Methods for Making and Using Endoxifen.

Company positioned to pursue expedited regulatory pathways in metastatic, neoadjuvant, and risk-reduction settings SEATTLE , Dec. 4, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company focused on transforming breast cancer treatment and prevention, announced the completion of a Type C meeting with the U.S. Food and Drug Administration ("FDA") on November 17, 2025, to review regulatory strategy for advancing (Z)-endoxifen. During the meeting, the FDA provided the Company feedback on potential expedited regulatory pathways and development options across metastatic disease, neoadjuvant treatment, and breast cancer risk-reduction settings.

Zillow predicts a slight uptick in home sales as pent-up demand meets improved affordability Home values are forecast to rise 1.2% in 2026, with the number of major markets seeing annual price declines projected to fall from 24 markets as of October to 12 next year. Zillow projects 4.26 million existing home sales next year — a 4.3% increase over 2025 — as improving affordability brings more demand back to the market.

SEATTLE , Dec. 2, 2025 /PRNewswire/ -- Zillow Group, Inc. (Nasdaq: Z and ZG), which is transforming the way people buy, sell, rent and finance homes, today announced Zillow Group will present at this year's Barclays 23rd Annual Global Technology Conference in San Francisco.  Chief Executive Officer Jeremy Wacksman will participate in a fireside chat on Thursday, Dec. 11, at 11:35 a.m.

Zillow Group, Inc. (ZG) Presents at UBS Global Technology and AI Conference 2025 Transcript

CAMBRIDGE, Mass. , Dec. 2, 2025 /PRNewswire/ -- Insilico Medicine ("Insilico"), a global leader in AI-powered drug discovery, and Atossa Therapeutics ("Atossa") (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel treatments for breast cancer and other serious conditions, announce the publication of a joint study evaluating the potential of (Z)-endoxifen for glioblastoma multiforme (GBM).

The scores aimed to predict a property's risk from a fires, floods and storms, but some in the real estate industry as well as homeowners have called them inaccurate.

DeNA (OTCMKTS:DNACF - Get Free Report) and Zillow Group (NASDAQ: Z - Get Free Report) are both computer and technology companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation. Insider and Institutional Ownership 71.0% of Zillow

Greatland Resources Ltd (AIM:GGP, OTC:GRLGF, ASX:GGP) has strengthened the growth case for its emerging West Dome Underground (WDU) opportunity at Telfer,...

Altech Batteries Ltd (ASX:ATC, OTC:ALTHF) has finalised the engineering design for its next-generation sodium-nickel-chloride (SNC) uninterrupted power...

Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) has secured formal grant of its Patent Family 4 in the Hong Kong Special Administrative Region, with expiry...

Imugene Ltd (ASX:IMU, OTC:IUGNF) has entered a strategic co-development collaboration with JW Therapeutics (Shanghai) Co. LTD (HKEX: 2126) to evaluate a...

Zillow (NASDAQ:Z) is positioned for another quarter of outperformance in the fourth quarter as US housing momentum shows signs of strengthening, according to analysts at Jefferies. The firm repeated its ‘Buy' rating on the real estate platform with a $100 price target, implying upside of about 35% from current levels.